MENLO PARK, Calif., Aug. 6, 2015 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and six months ended June 30, 2015.
Recent Accomplishments & Highlights:
- Achieved revenue of $11.4 million in the second quarter of 2015, an increase of 52% as reported and 81% on a constant currency basis over the same period of the prior year
- Received FDA approval for HF10 Spinal Cord Stimulation (SCS) therapy with superiority labeling and commenced U.S. launch
- Completed a successful follow-on underwritten public offering resulting in net proceeds to Nevro of approximately $118 million
- Publication of SENZA-RCT pivotal trial results in Anesthesiology
- SENZA-RCT 18-month results presented at the International Neuromodulation Society (INS) 12th World Congress in Montreal and results selected as the "2015 Best Clinical Abstract" at the International Spine Intervention Society meeting in Las Vegas, Nevada
- Over 4,000 chronic pain patients have benefited from HF10 therapy to date
"The organization continues to execute well with another milestone-packed quarter," said Michael DeMane, Chairman and CEO of Nevro. "I am pleased to see continued robust adoption and growing interest for HF10 therapy in international geographies. We are now underway with U.S. launch of the therapy making the technology available for the first time to leading pain management centers in the country. The positive reception from our physician and surgeon partners affirms our confidence in this therapy advance."
Second Quarter Financial Results
Revenue for the three months ended June 30, 2015 was $11.4 million versus $7.5 million during the same period of the prior year, representing 52% growth as reported. International revenue was $11.3 million, representing growth of 51% as reported and 80% in terms of constant currency. The increase in international revenue was primarily attributable to continued adoption of the Senza® system. U.S. revenue for the three months ended June 30, 2015 was approximately $53,000 since commencing U.S. launch with the first trial procedure performed on May 22, 2015.
Gross profit for the three months ended June 30, 2015 was $5.9 million, representing a 52% gross margin, up from $5.0 million, representing a 66% gross margin in the same period of the prior year. During the quarter, the company recorded a $1.2 million charge related to the writedown of inventory that did not conform to our product requirements. This resulted in a reduction of approximately eleven gross margin points. Additionally, while international revenues were negatively impacted by the appreciation of the U.S. dollar, costs were primarily incurred in U.S. dollars, which negatively impacted the overall gross margin for the period.
Operating expenses for the three months ended June 30, 2015 were $25.1 million, an increase of 101% compared to $12.5 million in the same period of the prior year. The increase in operating expenses was driven primarily by increased headcount and related personnel costs for the sales and marketing organization in support of the U.S. commercial launch as well as an increase in general and administrative costs associated with being a public company.
Loss from operations for the second quarter of 2015 was $19.2 million compared to $7.5 million for the same period of the prior year.
International Revenue Guidance for Full Year 2015
Nevro is increasing its previously issued guidance, now estimating international revenue for the full year 2015 to be in the range of $41 to $43 million, which represents an increase from 2014 in the range of 26% to 32% on a reported basis, and in the range of 44% to 52% using foreign exchange rates from the second quarter of 2015. Previous guidance for international revenue was in the range of $36 to $38 million.
Webcast and Conference Call Information
Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening to the conference call may dial (877) 201-0168 for domestic callers, or (647) 788-4901 for international callers (Conference ID: 73272901), or access the webcast on the "Investors" section of the company's web site at: www.nevro.com.
About Nevro
Headquartered in Menlo Park, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
